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Abstract
As the relative burden of community-acquired bacterial pneumonia among HIV-positive patients increases, adequate
prediction of case severity on presentation is crucial. We sought to determine what characteristics measurable on
presentation are predictive of worse outcomes. We studied all admissions for community-acquired bacterial pneumonia
over one year at a tertiary centre. Patient demographics, comorbidities, HIV-specific markers and CURB-65 scores on
Emergency Department presentation were reviewed. Outcomes of interest included mortality, bacteraemia, intensive
care unit admission and orotracheal intubation. A total of 396 patients were included: 49 HIV-positive and 347 HIV-
negative. Mean CURB-65 score was 1.3 for HIV-positive and 2.2 for HIV-negative patients (p< 0.0001), its predictive
value for mortality being maintained in both groups (p¼ 0.03 and p< 0.001, respectively). Adjusting for CURB-65 scores,
HIV infection by itself was only associated with bacteraemia (adjusted odds ratio [AOR] 7.1, 95% CI [2.6–19.5]). Patients
with< 200 CD4 cells/mL presented similar CURB-65 adjusted mortality (aOR 1.7, 95% CI [0.2–15.2]), but higher risk of
intensive care unit admission (aOR 5.7, 95% CI [1.5–22.0]) and orotracheal intubation (aOR 9.1, 95% CI [2.2–37.1]),
compared to HIV-negative patients. These two associations were not observed in the> 200 CD4 cells/mL subgroup
(aOR 2.2, 95% CI [0.7–7.6] and aOR 0.8, 95% CI [0.1–6.5], respectively). Antiretroviral therapy and viral load suppres-
sion were not associated with different outcomes (p> 0.05). High CURB-65 scores and CD4 counts< 200 cells/mL were
both associated with worse outcomes. Severity assessment scales and CD4 counts may both be helpful in predicting
severity in HIV-positive patients presenting with community-acquired bacterial pneumonia.
Keywords
HIV, AIDS, opportunistic infection, pneumonia, community-acquired pneumonia, clinical prediction rule, CURB-65 score
Date received: 26 May 2015; accepted: 18 August 2015
Introduction
Early since the introduction of highly active anti-
retroviral therapy (HAART) in the mid-1990s, morbid-
ity and mortality among human immunodeﬁciency
virus (HIV)-infected patients have decreased dramatic-
ally. Rates of opportunistic infections and AIDS-
deﬁning neoplasms registered a sharp decline, with a
resulting drop in the number of related hospitalisations
and deaths.1,2
Community-acquired pneumonia (CAP) is deﬁned
as an acute lower respiratory tract infection associated
with new radiographic shadowing for which there
is no other explanation and which is deemed to be
community-acquired, as opposed to hospital-acquired
or health care associated.3,4 HIV infection has been
consistently described as a major risk factor for
CAP,5–8 which is considered a stage 3 disease in the
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World Health Organization HIV staging classiﬁcation9
and an AIDS-deﬁning illness by the American Centers
for Disease Control and Prevention (CDC) when recur-
rent.10 Despite a reported decline in incidence over the
last two decades,7–8,11 this condition remains frequent
in this population, with its relative burden presently
greater than before.11–14 In fact, CAP among HIV-
infected patients has been found in some studies
performed in high-income settings to be the most
prevalent severe non-AIDS-deﬁning infection and one
of the most frequent reasons for hospital admis-
sion.11,12,15,16 Low CD4 cell counts, uncontrolled viral
replication and absence of HAART have been asso-
ciated with increased incidence.6,12,14–16
Research has addressed this topic since the beginning
of the HAART era, focusing on the course and outcome
of CAP in HIV-positive patients.5,13,15,17–19 HIV infec-
tion is a known risk factor for bacteraemia,5,19 but
apparently not for higher mortality5,18,20,21 or time to
clinical stability.20,21 Evidence on prediction of severity
and resulting guidance on risk stratiﬁcation and related
management remains heterogeneous.13,15,17,18
In order to assess CAP severity on presentation and
consequently guide therapeutic options, several predic-
tion scales based on clinical and laboratorial criteria
have been developed, which are nowadays widely used
and endorsed by clinical societies worldwide.3,4,22 The
Pneumonia Severity Index (PSI), developed in the
USA, uses a total of 20 variables, including clinical
background and signs, and venous and arterial blood
markers.23 CURB-65, introduced by researchers from
the UK, the Netherlands and New Zealand, uses a
more elementary prediction rule based on four clinical
and one laboratory parameter.3 Clinicians in the
Emergency Department (ED) are often faced with a
great deal of uncertainty in applying general clinical pre-
diction rules to HIV-positive patients and consequently
deciding site-of-care. A few observational works on this
ﬁeld, which evaluated the applicability of PSI in this
population, have consistently found that a high score
correlates with a higher risk of mortality.13,17,18 In one
study designed to analyse the association between naso-
pharyngeal Pneumococcus density in South African
HIV-positive patients with markers of disease severity
and poor outcome, no correlation between CURB-65
scores and mortality was found.24 Furthermore, it has
not been clearly established whether HIV infection per se
should be regarded as an additional independent prog-
nostic marker.
In this work, we aimed to assess the prognostic
importance of CURB-65 in the prediction of morbidity
and mortality among HIV patients presenting with
CAP. Our further goal was to determine if HIV sero-
positivity, greater immunosuppression, HAART use
and lack of virological control act as additional inde-
pendent prediction factors for worse outcomes.
Methods
Study design and setting
Using a retrospective cohort design, we studied all
admissions occurring over the year 2010 in a tertiary
teaching hospital centre in Lisbon, Portugal, which
were classiﬁed by attending ED physicians as CAP.
Participants, measurements and outcomes
Hospital electronic diagnosis code registry, clinical
notes, laboratory results and chest images were
reviewed. HAART prescription, lymphocyte subset
and viral load data were also assessed in Si.vida, a
Portuguese national network platform where updated
HIV-positive patients’ data are stored.
All admitted adult patients (18 years or older) who
met clinical and radiological criteria for pneumonia were
primarily included. Exclusion criteria comprised respira-
tory infections which were in the course of admission
found to be caused by mycobacteria or Pneumocystis,
either by molecular, microbiological or histopatho-
logical methods. Patients hospitalised within 90 days
prior to admission or meeting risk factors for health
care-associated pneumonia4 and patients with immuno-
suppression due to causes other than HIV infection
(ongoing chemo- or radiotherapy, haematological
malignancy, steroid use and asplenia) were also
excluded.
Baseline variables included demographic data,
comorbidities, HIV serostatus, lymphocyte subset
count, CURB-65 score (confusion, urea level, respira-
tory rate, blood pressure and age >65 years) on ED
admission. Patients were considered HIV-positive for
the purpose of this study, either due to previously
known chronic infection or as a result of a positive
screen conducted in the course of admission. The pri-
mary outcome of interest was in-hospital mortality.
Secondary outcomes were bacteraemia, ICU admission,
orotracheal (OT) intubation and length of hospital stay.
The study was granted ethical approval by the
Centre’s Institutional Review Board.
Statistical analysis
The dataset was constructed using Excel (Microsoft
Systems, Redmond, Washington, USA) and analysed
using Stata 13.1 (Stata Statistical Software: Release
13. College Station, Texas, USA: StataCorp LP).
A Chi square test and t-test were used to evaluate
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diﬀerences in baseline characteristics. Mantel-Haenszel
stratiﬁcation was used to adjust for age diﬀerences
when comparing categorical outcomes in relation
to HIV serostatus. Multivariate analysis was carried
out using linear and logistic regression, in order to
identify independent outcome predictors. A double-
sided p value lower than 0.05 was considered signiﬁ-
cant. Associations are mainly expressed as odds ratios
(OR) and adjusted odds ratios (aOR). Conﬁdence
intervals (CI) are shown for 95% levels.
Results
Over the study period, a total of 29,684 adult patients
were admitted, 753 of whom for clinically and
radiologically (chest radiograph or CT-scan)-conﬁrmed
pneumonia. After exclusion of 242 patients for health-
care-associated pneumonia and a further 199 for immu-
nosuppression due to other causes, a total of
396 patients met the study inclusion criteria: 49 HIV-
positive and 347 HIV-negative (Table 1). HIV-positive
patients were overall younger, predominantly men,
with a higher proportion of smokers and lower preva-
lence of diabetes and heart failure.
Data were available for calculation of CURB-65
in 91.4% (n¼ 362) of all patients. Mean CURB-65
scores were 1.3 points in HIV-positive and 2.2 points
in HIV-negative patients (p< 0.0001; age adjusted
p¼ 0.44).
In-hospital mortality was 4.1% (n¼ 2) for HIV-
positive and 12.1% (n¼ 42) for HIV-negative patients
(age aOR 1.1 CI [0.2–6.3] p¼ 0.90). Bacteraemia was
documented in 8.9% (n¼ 35) of all patients. Blood cul-
tures drawn from HIV-positive patients were more
likely to be positive (aOR 9.1 CI [3.1–27.2] p< 0.001).
In all, 11.6% (n¼ 46) were eventually admitted to an
ICU and 9.6% (n¼ 38) orotracheally intubated in the
course of their admission. HIV-positivity did not result
in signiﬁcant diﬀerences either in ICU admission (aOR
1.9 CI [0.7–4.8], p¼ 0.20) or OT intubation (aOR 1.4
CI [0.5–4.4] p¼ 0.58). Mean in-patient stay was 11.6
days, 9.3 for HIV-positive and 12.0 days for HIV-
negative patients (p¼ 0.12; age-adjusted p¼ 0.50).
Stratifying CAP severity according to CURB-65
scores into low, intermediate and high risk,3,25 there
was a signiﬁcant trend for higher mortality both in
HIV-positive and HIV-negative patients, whereas
associations with ICU admission and OT intubation
were signiﬁcant only in either one of the serogroups
(Table 2). Receiver operating characteristics (ROC)
curves and their respective areas under the curves
(AUCs) are depicted in Figure 1.
Lymphocyte subset determinations were available in
96% (n¼ 47), viral load and HAART use in 98%
(n¼ 48) of all HIV-positive patients. The median
CD4þT-lymphocyte cell count was 278 cells/mL
(inter-quartile range 111–541). A majority (58%,
n¼ 28) was on HAART, 40% (n¼ 20) having achieved
viral load suppression in the latest determination.
Linear regression showed a negative correlation
between CD4 count and length of stay (Figure 2).
Adjusting for comorbidities and CURB-65 score
values on multivariate logistic regression, HIV-
seropositivity did not independently predict mortality
(aOR 1.1 CI [0.2–5.4] p¼ 0.93), OT intubation (aOR
2.9 [0.9–9.2] p¼ 0.08) or ICU admission (aOR 1.9 CI
[0.7–5.4] p¼ 0.23). It did however predict bacteraemia
(aOR 7.1 CI [2.6–19.5] p< 0.001). Subgroup analyses
within HIV-positive patients depicted in Table 3, using
HIV-negative patients as a comparator, showed that
patients with CD4 counts below 200 cells/mL were at
higher risk of ICU admission and OT intubation,
whereas patients with counts above that value were
not. No independent eﬀect was seen for diﬀerent sub-
groups of viral load suppression and HAART use
regarding these outcomes. No subgroup was associated
with diﬀerent mortality and all were associated with
higher blood culture positivity.
Table 1. Baseline characteristics according to patient serostatus.
Baseline variables (n¼ 396) HIV-positive (n¼ 49) HIV-negative (n¼ 347) p Value
Men 38 (77.6%) 191 (55.0%) 0.003
Age (mean SD) (years) 45.3 13.5 67.8 21.2 <0.0001
Smoking 21 (42.9%) 77 (22.2%) 0.001
Diabetes 1 (2.0%) 74 (21.3%) 0.001
Heart failure 3 (6.1%) 96 (27.7%) 0.001
COPD 9 (18.4%) 95 (27.4%) 0.2
CKD 2 (4.1%) 31 (8.9%) 0.4
SD: standard deviation; COPD: chronic obstructive lung disease; CKD: chronic kidney disease.
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Discussion
Our study suggests that CURB-65 scores on ED pres-
entation are useful in discriminating mortality risk
groups, regardless of HIV serostatus. HIV infection
overall was associated with lower CURB-65 scores,
higher rates of bacteraemia and similar CURB-65-
controlled clinical outcomes. However, the subgroup
of HIV-positive patients with CD4 counts lower than
200 cells/mL had a higher chance of being admitted to
an ICU and of being intubated.
To our knowledge, this is the ﬁrst work designed to
study the CURB-65 score among HIV-positive patients
and its ﬁndings suggest this score’s prognostic perform-
ance is maintained in this population. Its reduced
number of easily measurable variables makes its use
very convenient in busy EDs and primary care centres.
Compared to other scores such as PSI, its performance
as a prediction rule has been widely validated,26,27 one
large meta-analysis indicating it might be less sensitive
but more speciﬁc.26
HIV-positive patients in this study had signiﬁcantly
lower severity scores than their seronegative counter-
parts, similar to what was observed in the CAPO inter-
national cohort study.20,21 In our case, the diﬀerence
can be explained by HIV-positive patients being
younger, as age >65 years is a prognostic feature
which contributes one point in the CURB-65 score,
and there were no diﬀerences with respect to age-



















Figure 1. ROC curves illustrating performance of CURB-65 in predicting mortality for HIV-positive (AUC 0.880) and HIV-negative
patients (AUC 0.804).
Table 2. Risk stratification according to CURB-65 and its association with outcomes.
CURB-65 mortality risk score n (%)
Chi square test for trend
Mortality OT intubation ICU admission
HIV-negative (n¼ 317) Low (0–1) 99 (31.2%) p< 0.001 p¼ 0.04 p¼ 0.17
Intermediate (2) 85 (26.8%)
High (3–5) 133 (43.0%)
HIV-positive (n¼ 48) Low (0–1) 28 (58.3%) p¼ 0.03 p¼ 0.07 p¼ 0.003
Intermediate (2) 16 (33.3%)
High (3–5) 4 (8.3%)
OT: orotracheal; ICU: intensive care unit.
Almeida et al. 1001
 at Hosp do Divino Espirito PARENT on October 13, 2016std.sagepub.comDownloaded from 
factors guided clinicians in their decision to admit. One
possible explanation could be that, compared to the
overall population, HIV-positive patients have a
higher prevalence of drug use and/or social vulner-
ability, making more individuals among them unreli-
able for outpatient therapy. Another potential reason
could be that clinicians perceived HIV infection itself as
a risk factor lowering the threshold for admission, as
was proposed by Malinis et al.21 regarding the CAPO
study. Both factors could have confounded our study.
The fact that there is a linear relation between CD4
cell count and length of stay and that a stratum-speciﬁc
independent eﬀect was observed for patients with CD4
cell counts <200 cells/mL regarding ICU admission and
OT intubation suggests that this variable played a role
in all these outcomes. Admission periods could have
been protracted by a longer time to achieve clinical
stability, but the higher risk of concomitant opportun-
istic diseases is also a consideration. More frequent
ICU admission and OT intubation leads us to hypothe-
sise that a greater impairment of cellular immunity put
patients at risk of respiratory failure and/or severe
sepsis. Accordingly, research has shown that CD4 cell
depletion not only contributes to bloodstream invasion
by Streptococcus pneumoniae but also to deregulated
inﬂammatory response through impaired release of
proinﬂammatory cytokines.28
Stemming from diﬀerent methodologies, there is
disagreement in the association between lower CD4
cell counts and worse outcomes, including multi-
lobar consolidation, longer time to clinical stability
and increased mortality. Some studies have reported
no impact of this marker on CAP outcome,11,17
whereas others have conversely found a signiﬁcant
impact on mortality, prompting authors to recom-
mend admission of all patients in the <200 cells/mL
subgroup.13,15,29 Taking into account our results,
in addition to CURB-65 scores, low CD4 cell counts
seem to be independent predictive factors in the
severity assessment of HIV-positive patients present-
ing with CAP. Both may thus be taken into con-
sideration to aid clinical judgment when deciding
site-of-care.
The major limitation of this study was the relatively
small size of its HIV-positive cohort and the limited
number of primary events in this population. Other
limitations include its retrospective design and the
fact that it was conducted in a single urban tertiary
centre, which may limit its generalisability.
Nevertheless, it is expected that our assumptions
apply to other so-called high-income settings where
HAART is widely accessible. Not all patients with
unknown serostatus were tested for HIV, which could
have resulted in underestimation of seropositivity and
misclassiﬁcation bias. Furthermore, patients presenting
with CAP who were discharged from the ED were not
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Figure 2. Length of hospital stay as a function of CD4 cell count in HIV-positive patients (linear regression slope –0.01 CI
[–0.02; –0.002] p¼ 0.01).
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A larger multi-centric study is imperative to develop
a reliable prediction model, which takes into account
speciﬁc aspects of HIV patients with CAP.
Conclusions
The performance of CURB-65 in predicting mortality
appears to be maintained in HIV-positive patients. HIV
infection overall was not an intrinsic independent sever-
ity predictor in patients presenting with CAP. However,
patients with lower CD4 cell counts may have a higher
risk for OT intubation, ICU admission and longer
admission periods. In addition to using severity assess-
ment scores such as CURB-65, clinicians should also
bear in mind the prognostic value of CD4 counts.
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